COVID-19: Aerosol Transmission of Severe Acute Respiratory Syndrome Coronavirus of Coronavirus Disease 2019

Sponsor
Hospital Italiano de Buenos Aires (Other)
Overall Status
Completed
CT.gov ID
NCT04609774
Collaborator
(none)
8
1
1.8
4.5

Study Details

Study Description

Brief Summary

There is little information on the characteristics of airborne severe acute respiratory syndrome coronavirus containing aerosols, their concentration, or their infectivity.The aim was to determine airborne severe acute respiratory syndrome coronavirus transmission, their infectivity in different areas such as patient's room and in medical staff área.

Condition or Disease Intervention/Treatment Phase
  • Other: Severe Acute Respiratory Syndrome CoronaVirus 2 detection

Detailed Description

The Corona Virus Disease 2019 is rapidly spreading throughout the world. Aerosol is a potential transmission route.

The transmission of severe acute respiratory syndrome coronavirus in humans is thought to be via at least 3 sources: 1) inhalation of liquid droplets produced by and/or 2) close contact with infected persons and 3) contact with surfaces contaminated with severe acute respiratory syndrome coronavirus. There are many respiratory diseases spread by the airborne route such as tuberculosis, measles and chickenpox. Several studies suggested that airborne spread may have played an important role in the transmission of that disease. At present, there is little information on the characteristics of airborne severe acute respiratory syndrome coronavirus containing aerosols, their concentration, or their infectivity.

The aim was to determine airborne severe acute respiratory syndrome coronavirus 2 transmission, their infectivity in in different areas such as patient's room and in medical staff area.

Methods

Cross sectional study of samples from environmental of patient´s room, and medical staff area. Samples will be taken of air using microbial air monitoring systems, and from different surfaces of patient's room and medical staff area, such as computers, mouse and personal protective equipment using cotton swabs. Viral RNA will be determined using Real-Time-Polymerase-Chain Reaction. In positive samples infectiveness will be determined by cell culture under biosecurity conditions.

Statistical analysis will be performed to determine prevalence of positive samples and positive cell culture whit STATA version 15.1.

informed consent will be obtained from all participants

Study Design

Study Type:
Observational
Actual Enrollment :
8 participants
Observational Model:
Case-Crossover
Time Perspective:
Cross-Sectional
Official Title:
Aerosol Transmission of Severe Acute Respiratory Syndrome Coronavirus: a Dilemma
Actual Study Start Date :
Oct 8, 2020
Actual Primary Completion Date :
Nov 20, 2020
Actual Study Completion Date :
Dec 1, 2020

Outcome Measures

Primary Outcome Measures

  1. Airborne transmission of Severe Acute Respiratory Syndrome CoronaVirus 2 [9 moths]

    Detection of Severe Acute Respiratory Syndrome CoronaVirus 2 RNA by Real Time Polymerase Chain Reaction and cell culture

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adults 18 years and more, with diagnoses of COVID-19 96 hours since the beginning of symptoms.

  • Medical staff, nurses and/or physician taking care of patient whit COVID-19

Exclusion Criteria:
  • Unwilling to give informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Italiano de Buenos Aires Ciudad autónoma de Buenos Aires Argentina C1199ABB

Sponsors and Collaborators

  • Hospital Italiano de Buenos Aires

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
VANINA LAURA PAGOTTO, principal investigator, Hospital Italiano de Buenos Aires
ClinicalTrials.gov Identifier:
NCT04609774
Other Study ID Numbers:
  • 1345
First Posted:
Oct 30, 2020
Last Update Posted:
Feb 4, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by VANINA LAURA PAGOTTO, principal investigator, Hospital Italiano de Buenos Aires
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 4, 2021